Clinical Report: Obesity Prevalence and Contributing Factors in Schizophrenia

Overview

This systematic review found that the incidence proportion of obesity among patients with schizophrenia is 33.0%. Key risk factors include female sex, diabetes, and specific antipsychotic medications.

Background

Obesity is a significant concern for individuals with schizophrenia, as they are at a higher risk for metabolic disorders and related complications. The prevalence of obesity in this population is notably higher than in the general population, which can adversely affect treatment outcomes and quality of life. Identifying and addressing these risk factors is crucial for improving patient care.

Data Highlights

Key Findings

• The incidence proportion of obesity in patients with schizophrenia is 33.0%.
• Female sex is associated with a higher risk of obesity (OR = 1.14).
• Diabetes significantly increases the risk of obesity (OR = 2.36).
• Use of olanzapine is linked to a substantial increase in obesity risk (OR = 7.40).
• Combined antipsychotic therapy also raises obesity risk (OR = 3.19).

Clinical Implications

Clinicians should prioritize early screening for obesity in patients with schizophrenia, particularly those on antipsychotic medications. Targeted interventions, including lifestyle modifications and pharmacological strategies, are essential to mitigate obesity-related health risks in this population.

Conclusion

The findings underscore the importance of recognizing and addressing obesity in patients with schizophrenia to enhance their overall health outcomes. Implementing proactive management strategies can significantly improve quality of life for these individuals.

References

1. BMC Psychiatry (Springer, 2025) -- Prevalence of metabolic syndrome in Chinese patients with schizophrenia: a systematic review and meta-analysis
2. BMC Psychiatry (Springer, 2025) -- Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis
3. BMC Psychiatry (Springer, 2025) -- Cortical surface area as a stronger mediator of the waist-to-height ratio and cognitive impairment link in patients with first-episode schizophrenia compared to body mass index and waist-hip ratio
4. Standards of Care in Diabetes | ADA Clinical Guidelines
5. NHS England » Improving the physical health of people living with severe mental illness
6. BMC Psychiatry (Springer) — Suicide risk, psychopathology and cognitive impairments in schizophrenia with insomnia: a large-scale cross-sectional study
7. WHO issues global guideline on the use of GLP-1 medicines in treating obesity
8. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial
9. Standards of Care in Diabetes | ADA Clinical Guidelines
10. NHS England » Improving the physical health of people living with severe mental illness
11. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis - ScienceDirect
12. Interventions to prevent antipsychotic-induced weight gain and metabolic complications in individuals with a first-episode psychosis and minimal antipsychotic exposure: a systematic review and meta-analysis | Psychological Medicine | Cambridge Core